Singapore markets closed

Bausch Health Companies Inc. (BHC)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
7.580.00 (0.00%)
As of 10:04AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close7.58
Bid7.56 x 1200
Ask7.57 x 1300
Day's range7.50 - 7.67
52-week range4.00 - 29.31
Avg. volume8,892,064
Market cap2.718B
Beta (5Y monthly)1.21
PE ratio (TTM)50.53
EPS (TTM)0.15
Earnings date31 Oct 2022 - 04 Nov 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend date10 Nov 2010
1y target est17.22
  • CNW Group

    Seasonal Affective Disorder (SAD) Is Now a Recognized Diagnosis in the CMS Tabular Index, Accessible to Prescribers Oct. 1, 2022

    Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") is continuing its commitment to improving lives with the announcement of modifications within the Tabular Index, specifically for the prevention and treatment of SAD from the Centers for Medicare & Medicaid Services (CMS). Now, all appropriate codes have been combined into a bundle for SAD which allows healthcare professionals to further clarify a diagnosis in an easy-to-understand index tab and send all diagnoses for SAD to one simp

  • CNW Group


    Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal (GI) and liver diseases and disorders, announced today, their endorsement of the implementation of K76.82, an ICD-10 code from the Centers for Medicare & Medicaid Services (CMS) for hepatic encephalopathy (HE), a complication of cirrhosis

  • CNW Group

    Bausch Health Announces Final Results and Expiration of Exchange Offers and Consent Solicitations

    Bausch Health Companies Inc. (NYSE/TSX: BHC) (the "Company") announced today the final results and expiration of its previously announced offers (the "Exchange Offers") to exchange the existing senior notes set forth in the table below (the "Existing Senior Notes") for up to an aggregate principal amount of $4.0 billion (the "Maximum New Secured Notes Amount") of New Secured Notes (as defined below) and the related solicitations of consents (the "Consent Solicitations" and, together with the Exc